Oncology · PARP InhibitorTrial Updateclinicalmid-term

AstraZeneca initiates post-marketing surveillance for Lynparza in South Korea

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/26/2026, 6:02:55 AM

Assessment confidence: 89% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

AstraZeneca's post-marketing surveillance for Lynparza is crucial as it evaluates the drug's safety and effectiveness in real-world settings. The outcomes of this study could significantly impact Lynparza's competitive positioning in the oncology market, particularly against other PARP inhibitors. Regulatory context from FDA (Verified Clinical Benefit | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 24 ranked evidence items (24 high-relevance).

Strategic Assessment

Portfolio teams should monitor the outcomes of this study to assess Lynparza's long-term viability and competitive edge in the oncology market. The strongest clinical anchor is Korean Post-marketing Surveillance for Xeljanz XR (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Oncology · PARP Inhibitor, 6 regulatory and 4 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from Etcamah Approved in EU for 1st-Line Advanced ER+ Breast Cancer (Humanexa Signals) — entity match (astrazeneca). Secondary pressure from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer. This study may provide critical data on Lynparza's performance post-approval, potentially influencing its market position against competitors in the PARP inhibitor space.

Regulatory Outlook

Regulatory risk is concentrated around Verified Clinical Benefit | Cancer Accelerated Approvals (FDA). Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval). The findings may affect future regulatory considerations, including labeling updates or additional requirements for ongoing safety monitoring.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Mitigating Risks of Compounded Drugs Through Surveillance) could weigh on AstraZeneca through agency review timelines and labeling constraints if follow-through weakens.
Clinical risk from ClinicalTrials.gov (Korean Post-marketing Surveillance for Xeljanz XR) could weigh on AstraZeneca through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The results of this surveillance could influence market share and revenue for Lynparza, depending on its demonstrated effectiveness and safety in the post-approval phase.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for AstraZeneca may improve if Clinical transitions amid rapid expansion: a 16-year retrospective analysis of ultrasound-guided high-intensity Focused ultrasound (USgHIFU) for uterine fibroids and adenomyosis in Korea and the neces (PubMed) delivers favorable follow-through.
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and final outcomes of the safety and effectiveness assessments.
Timeline shift beyond mid term would change urgency.
Outcome from Verified Clinical Benefit | Cancer Accelerated Approvals would change the regulatory/clinical read.
Outcome from Ongoing | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (approval)
FDA document
View source
Mitigating Risks of Compounded Drugs Through Surveillance
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Frutas Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E.
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Korean Post-marketing Surveillance for Xeljanz XR
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Etcamah Approved in EU for 1st-Line Advanced ER+ Breast Cancer
Humanexa Signalshigh relevance
Entity match (astrazeneca)
FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)
Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer
Humanexa Signalshigh relevance
Sponsor/company relevance (AstraZeneca)

Clinical transitions amid rapid expansion: a 16-year retrospective analysis of ultrasound-guided high-intensity Focused ultrasound (USgHIFU) for uterine fibroids and adenomyosis in Korea and the neces
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Role of an Ayurvedic formulation 'Kalyanaka Ghrita' in mild cognitive impairment: A single-patient, quasi-randomized, controlled, open-label N-of-1 trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Integrated exposure-based therapy for co-occurring post-traumatic stress and substance use among young people: a randomized controlled trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Lynparza

Commercial impact

medium

The results of this surveillance could influence market share and revenue for Lynparza, depending on its demonstrated effectiveness and safety in the post-approval phase.

Regulatory impact

medium

The findings may affect future regulatory considerations, including labeling updates or additional requirements for ongoing safety monitoring.

What to watch

Key milestones include interim results and final outcomes of the safety and effectiveness assessments.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.